BXCL501 is an oral thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BXCL501 ...

Dexmedetomidine may be renoprotective by reducing ischemia-reperfusion injury, according to the investigators. Dexmedetomidine may reduce the odds of delayed graft function following ...

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) can rapidly relieve mild to moderate acute agitation in patients with bipolar disorder (BD), ...

For the study, researchers randomly assigned patients to receive dexmedetomidine, a sedative, or a saline placebo infusion during surgery and for two hours while in recovery. They assessed patients ...

Please provide your email address to receive an email when new articles are posted on . At 7 and 42 days postpartum, women who received dexmedetomidine had lower positive postpartum depression rates.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Among ...

Please provide your email address to receive an email when new articles are posted on . DALLAS — Critically ill patients undergoing mechanical ventilation in the ICU who received early sedation with ...

A study published in the June 2011 issue of the Annals of Pharmacotherapy indicates that increasing doses of the drug dexmedetomidine may not enhance sedation in critically ill patients, according to ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dexmedetomidine Sales, Price Analysis, & Sales Forecast - 2017" report to their offering. Find out the sales of ...